NewEdge Advisors’s ImmunityBio IBRX Stock Holding History

NewEdge Advisors’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.06K	Hold	350	–	–	﹤0.01%	3835
2026 Q1	$2.69K	Hold	350	–	–	﹤0.01%	3744
2025 Q4	$693	Hold	350	–	–	﹤0.01%	4016
2025 Q3	$861	Hold	350	–	–	﹤0.01%	3897
2025 Q2	$924	Sell	350 -1	-0.3%	-$3	﹤0.01%	3726
2025 Q1	$1.06K	Hold	351	–	–	﹤0.01%	3616
2024 Q4	$899	Buy	351 +1	+0.3%	+$4	﹤0.01%	3579
2024 Q3	$1.3K	Hold	350	–	–	﹤0.01%	3463
2024 Q2	$2.21K	Buy	+350	New	+$2.31K	﹤0.01%	3311
2023 Q3	–	Sell	-250	Closed	-$695	–	3556
2023 Q2	$695	Hold	250	–	–	﹤0.01%	3293
2023 Q1	$455	Hold	250	–	–	﹤0.01%	3246
2022 Q4	$1	Buy	+250	New	+$1.37K	﹤0.01%	4017

Other funds holding IBRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

NewEdge Advisors's IBRX Position: Q2 2026 in Review

NewEdge Advisors held its ImmunityBio (IBRX) position steady in Q2 2026 at 350 shares worth $3.06K. The position accounts for ﹤0.01% of the portfolio, ranked #3835.

NewEdge Advisors first reported a position in IBRX in Q4 2022 and has held it in 12 quarters since. 405 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

NewEdge Advisors held 350 shares of ImmunityBio worth $3.06K as of Q2 2026.
NewEdge Advisors left its ImmunityBio share count unchanged in Q2 2026.
ImmunityBio made up ﹤0.01% of NewEdge Advisors's portfolio in Q2 2026, its #3835 holding.
NewEdge Advisors first reported a position in ImmunityBio in Q4 2022 and has held it in 12 quarters since.
405 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on NewEdge Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.